Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2020

View Archived Issues

Microglia protect brain via inhibition

NOX5 is a therapeutic target in diabetic kidney disease

Caladrius initiates proof-of-concept study of CLBS-119 for repair of COVID-19-induced lung damage

Hisamitsu Pharmaceutical initiates phase III study of HP-5070 in Japan

Fluvoxamine reduced the likelihood of hospitalization in patients with mild COVID-19

Topline data presented from phase III GALACTIC-HF study of omecamtiv mecarbil

TLC receives approval in Australia and Taiwan for phase I study of TLC-19

CNS leukemia cells depend on fat enzyme to survive and grow

Final data for depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma

Takeda Pharmaceutical patents RIP-2 kinase inhibitors

Yumanity Therapeutics presents new SCD inhibitors

EMPOWER-Lung 1 data for cemiplimab as first-line monotherapy in NSCLC with PD-L1 >= 50%

U.S. researchers identify muscarinic M4 receptor antagonists

Sorrento discovers Salicyn-30 as new inhibitor of SARS-CoV-2 infection in vitro

Saniona AB discloses new KCNN4 blockers

Citius licenses Novellus' iPSC-derived mesenchymal stem cells for acute respiratory conditions

FDA accepts Aprea's IND for APR-548 for TP53 mutant MDS

Spartina developing SIREN technology for COVID-19

BioAtla and BeiGene amend BA-3071 agreement to grant exclusive global license

Selective PDEB inhibitor shows promising preclinical results for the treatment of cocaine addiction

Bavituximab plus pembrolizumab show promising activity in advanced gastric or GEJ cancer

First-in-human data for RO-7122290, a FAP-targeted 4-1BB agonist

Phase IIb study of lenabasum in cystic fibrosis does not meet primary endpoint

FDA clears IND for HLX-70 to treat COVID-19

Phase III study of somatrogon for growth hormone deficiency meets primary endpoint

ILC's Alfacyte shows promise in vitro against SARS-CoV-2

Vincera signs license agreement with Bayer for early development oncology portfolio

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...